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NLRP3 inﬂammasomeAge-relatedmacular degeneration (AMD) is the leading cause of irreversible blindness in the elderly of industri-
alized nations, and there is increasing evidence to support a role for chronic inﬂammation in its pathogenesis. Mi-
tochondrial DNA (mtDNA) has been recently reported to be pro-inﬂammatory in various diseases such as
Alzheimer's and heart failure. Here, we report that intracellular mtDNA induces ARPE-19 cells to secrete inﬂam-
matory cytokines IL-6 and IL-8, which have been consistently associated with AMD onset and progression. The
induction was dependent on the size of mtDNA, but not on speciﬁc sequence. Oxidative stress plays a major
role in the development of AMD, and our ﬁndings indicate that mtDNA induces IL-6 and IL-8 more potently
when oxidized. Cytokine induction was mediated by STING (Stimulator of Interferon Genes) and NF-κB as
evidenced by abrogation of the cytokine response with the use of speciﬁc inhibitors (siRNA and BAY 11-7082,
respectively). Finally, mtDNA primed the NLRP3 inﬂammasome. This study contributes to our understanding
of the potential pro-inﬂammatory role of mtDNA in the pathogenesis of AMD.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial damage and dysfunction are associated with aging
and the development of neurodegenerative diseases [1,2], including
age-related macular degeneration (AMD) [3,4]. The examination of ret-
inas from patients with AMD has consistently revealed mitochondrial
DNA (mtDNA) damage and a decreased capacity for repair [3–7].
More speciﬁcally, ultrastructural studies in human eyes point to an
age-related decline in the number and structural integrity of mitochon-
dria in the retinal pigment epithelium (RPE), and a larger decline in eyes
with AMD [8]. Although it remains uncertain whether this ﬁnding is a
cause or a consequence of disease, mitochondrial damage can be
conceptualized to contribute to the development of AMD by way of in-
creased oxidative stress and deregulated apoptosis and necrosis, which
culminate in RPE death [4].
Inﬂammation is another plausible link betweenmitochondrial dam-
age and disease. In diverse pathologies that cause cell injury or death,
mitochondria can act as amajor source of damage-associatedmolecular
patterns (DAMPs) [9]. These are danger signals of various origins that
act by engaging the intracellular or extracellular pattern recognition
receptors (PRRs) in order to stimulate an immune response andetary or commercial interest in
r Inﬁrmary, 243 Charles Street,
s).cytokine production. Among the proposed DAMPs, mtDNA has received
considerable attention due to its immunostimulatory potential when
uncontained [9]. In fact, mtDNA release has been reported in various
pathologic conditions, including rheumatoid arthritis [10], cardiomyop-
athy [11], trauma [12], systemic inﬂammation [13–17], and neurode-
generation [18,19]. Since inﬂammation is an emerging major feature
of AMD, and given the compromised structural integrity of mitochon-
dria in the RPE of AMD patients, we hypothesized that mtDNA release
is potentially proinﬂammatory in the pathogenesis of AMD.
In particular, mtDNA has been found to induce the pro-
inﬂammatory cytokines IL-6 and IL-8 in vitro and in vivo [12,13,
17–20]. Both of these cytokines have been associated with AMD
progression [21–25] and the development of choroidal neovasculariza-
tion (CNV) [26–28]. In macrophages, mtDNA induces the NOD-like re-
ceptor family, pyrin domain containing 3 (NLRP3) inﬂammasome [29,
30], which has also been recently reported to be involved in the path-
ogenesis of AMD [31–33]. NLRP3 activation leads to cleavage of the
pro-form of caspase-1 into its mature form, with the latter cleaving
the pro-forms of IL-1β and IL-18 into their mature forms, which are
subsequently secreted by the cell [34]. Since the RPE is directly involved
in the pathogenesis of AMD [35], we thought it meaningful to examine
whether mtDNA can induce the pro-inﬂammatory cytokines IL-6 and
IL-8, and the NLRP3 inﬂammasome in ARPE-19 cells.
In this study, we report that mtDNA stimulates IL-6 and IL-8 secre-
tion as well as priming of the NLRP3 inﬂammasome in ARPE-19 cells.
Those effects were mediated by a common pathway involving Stimula-
tor of Interferon Genes (STINGs), an adaptor protein that is increasingly
being viewed as a central mediator of the DNA sensing pathways [36].
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tochondrial damage and inﬂammation in AMD based on the proinﬂam-
matory potential of mtDNA.
2. Materials and methods
2.1. Cell lines and reagents
ARPE-19 cells (CRL-2302), THP-1 cells (TIB-202), and RPMI-1640
medium (30-2001) were purchased from the American Type Culture
Collection (ATCC) (Manassas, VA). Human primary retinal pigment ep-
ithelial cells (hRPE) (194987) were obtained from Lonza (Walkersville,
MD). Dulbecco's Modiﬁed Eagle Medium (DMEM/F-12) (11330-057),
heat-inactivated fetal bovine serum (HI-FBS) (10438-026) and
Penicillin-Streptomycin (15140122) were purchased from Life Tech-
nologies (Grand Island, NY). HP X-tremeGene transfection agent
(06366244001) was obtained from Roche (Indianapolis, IN), recombi-
nant human IL-1α (200-LA-010) from R&D Systems (Minneapolis,
MN), and Bay 11-7082 inhibitor (196870) from EMDMillipore (Billerica,
MA). Anti-IL-18 antibody (ab137664), anti-IL-6 antibody (ab32530), and
anti-TATA binding protein (TBP) (51841) were obtained from Abcam
(Cambridge, MA). Anti-IL-1β antibody (MAB201), anti-IL-8 antibody
(MAB208), and anti-STING (MAB7169) were purchased from R&D Sys-
tems. Anti-caspase-1 (sc-515) was purchased from Santa Cruz Biotech-
nology (Dallas, TX). Anti-β-tubulin antibody (2128), anti-A20 (5630)
and HRP-linked secondary antibodies (7074S, 7076S) were obtained
from Cell Signaling Technology (Danvers, MA). ELISA kits for IL-1β
(DLB50), IL-18 (7620) and IL-8 (D8000C) were purchased from R&D.
Taq Polymerase (M0267S) was purchased from New England Biolabs
(Ipswich, MA).
2.2. Cell culture
ARPE-19 cells were maintained in DMEM/F-12 medium supple-
mented with 10% heat-inactivated FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin. THP-1 cells were grown in RPMI-1640
medium supplemented with 10% HI-FBS, 100 U/mL penicillin,
100 μg/mL streptomycin, and 50 μM 2-mercaptoethanol. All cells
were grown in humidiﬁed 5% CO2 at 37 °C and passaged every
2–3 days.
2.3. Preparation of mtDNA
Total DNA was extracted from ARPE-19 cells using QIAamp DNA
mini kit (51304) from Qiagen (Valencia, CA) according to the
manufacturer's protocol. From the extracted DNA, speciﬁc mtDNA
fragments were ampliﬁed by PCR on Bio-Rad BiCycler (Hercules,
CA) using primers and methods from a published protocol [37]. The
PCR products were run on a gel to verify speciﬁcity before being
puriﬁed using a PCR puriﬁcation kit (28104) from Qiagen. The
concentration of DNA was then measured using NanoDrop 2000
(ThermoFisher Scientiﬁc, Waltham, MA). Total DNA template was
undetectable in the ﬁnal eluate as determined by blank controls. To
generate oxidized mtDNA, 8-oxo-dGTP (N-2034) from TriLink
Biotechnologies (San Diego, CA) was added to the PCR reaction mix-
ture at the same concentration as the other nucleotides. To generate
FAM-tagged mtDNA, FAM-tagged primers were used. All primers
were ordered from the Massachusetts General Hospital DNA core
facility (Boston, MA).
2.4. mtDNA transfection into cells
ARPE-19 cells were seeded in 24-well plates at a density of 3 × 104
cells/well in complete DMEM/F12 medium. The following day, IL-1α
was added at 5 ng/mL to prime the cells. 24 h later, culture medium
was changed to antibiotic-free DMEM/F12 medium supplementedwith 1% FBS, and cells were transfected at 70–80% conﬂuence with
1 μg/mLmtDNA using HP X-tremeGene agent at a ratio of 1:1 accord-
ing to the manufacturer's protocol. Transfection agent alone was
used as a control for all experiments. 48 h later, culture media were col-
lected and cells lysedwith NP40 lysis buffer (Invitrogen) supplemented
with protease inhibitors (Complete Mini, Roche). For THP-1 experi-
ments, 1.5 × 106 cells were seeded in each well of a 6-well plate in
complete RPMI medium supplemented with 200 nM PMA to allow dif-
ferentiation into macrophages. 24 h later, medium was renewed and
LPS added at 500 ng/mL to prime the cells. 3 h later, medium was
changed to antibiotic-free RPMI medium and transfection of mtDNA
was performed as per above. 24 h later, culture media and cell lysates
were collected as per above.
2.5. Western blot
Total protein concentration was determined by DC Protein Assay
(Bio-Rad, Philadelphia, PA, US). Equal amounts of total protein (for cell
lysates) or culture medium (for secreted cytokines) were loaded on a
NUPAGE 4-12% bis-tris polyacrylamide gel (Life Technologies, Grand
Island, NJ) and subjected to electrophoresis. The proteins were trans-
ferred to a PVDF membrane (Millipore, Billerica, MA), and the mem-
brane was subsequently blocked with non-fat milk and incubated
with primary antibodies against IL-8 and capsase-1 at 1:500; IL-18,
A20, and TBP at 1:1000; IL-1β STING, IL-6 and β-tubulin at 1:2000.
The membrane was then washed and incubated with secondary
antibodies conjugated to horseradish peroxidase (Cell Signaling Tech-
nology) at 1:10000. The membrane was developed with enhanced
chemiluminescence (ECL Select) (GE Healthcare, Wauwatosa, WI).
The intensity of protein bands was quantiﬁed using the software
Image Lab 4.1 (Bio-Rad).
2.6. mtDNA tracking
ARPE-19 cells were seeded on EZ Slides (PEZGS0416, Millipore) at
5 × 104 cells/well in antibiotic-free medium and allowed to settle over-
night. The following day, cells were transfected with 1 μg/mL of FAM-
tagged mtDNA using HP X-tremeGene agent at a ratio of 1:1 according
to the manufacturer's protocol. 24 h later, cells were carefully washed
with PBS before ﬁxation in 4% PFA for 5 min. Afterwards, cells were
washed again with PBS and mounted using Vectashield mounting
medium with DAPI (H-1200) (Vector Laboratories, Burlingame, CA).
Slides were visualized on Zeiss Axio Imager M2.
2.7. MTT viability assay
ARPE-19 cells were transfectedwithmtDNA in a 96-well plate under
the same conditions outlined above. 48 h later, cells were washed with
PBS and incubated for 3 h with 0.5 mg/mL MTT (Life Technologies)
dissolved in PBS. The formed formazan crystals were dissolved by
adding 100 μL of acidiﬁed (0.04 N HCl) isopropanol (Sigma-Aldrich,
St. Louis, MO) to each well. Absorbance was read at 590 nm using the
SpectraMax190 Microplate Reader (Molecular Devices, Sunnyvale, CA).
2.8. siRNA experiments
For STING knockdown veriﬁcation, ARPE-19 cells in 6-well plates
were transfected at 70–80% conﬂuence with 20 nM of either STING
siRNA (Qiagen) or control siRNA in antibiotic-free DMEM/F12 medium
using RNAiMAX (Invitrogen) according to the manufacturer's protocol.
48 h later, mediumwas renewed and the same treatment was repeated
for 48 h, after which cell lysates were collected and immunoblotted for
STING. For STING knockdown experiments, ARPE-19 cells were seeded
in 6-well plates at a density of 2 × 105 cells/well in antibiotic-freemedi-
um. The following day, they were primed with 5 ng/mL IL-1α and
transfected with 20 nM of STING or control siRNA for 48 h using the
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and siRNA (20 nM)were co-transfected using HP X-tremeGene reagent
at a 1:1 ratio as per manufacturer's instructions. 48 h later, culture
media and cell lysates were collected for analysis.
2.9. p65 NF-κB nuclear translocation
ARPE-19 cells were transfected with mtDNA in 100 mm dishes
under the same conditions outlined above. 24 h later, nuclei were ex-
tracted using a kit (40010) (Active Motif, Carlsbad, CA) and proper nu-
clear fractionation was veriﬁed by western blot with TATA binding
protein and b-tubulin. p65 NF-κB was quantiﬁed in the nuclear extracts
using TransAM NF-κB ELISA (43296) (Active Motif) after compensation
for total protein concentration.
2.10. Caspase-1 activity
ARPE-19 cellswere transfectedwithmtDNA in glass-bottom24-well
plates under the same conditions outlined above. 24 h later, FAM-
YVAD-FMK (#97) (Immunocytochemistry technologies, Bloomington,
MN), a probe speciﬁc to caspase-1, was added at the concentration
recommended by the manufacturer. After a 2-hour incubation at 37 °C
and 5% CO2, Hoechst was added to the wells at 1 μg/mL and cells were
reincubated for 10 min. Cells were washed carefully with PBS and
visualized using Zeiss AxioObserver 21.
2.11. Statistical analysis
All experiments were performed three independent times unless
otherwise noted. Statistical analysiswas performed on JMP Pro software
version 11.2.0 from SAS (Cary, NC). Results are expressed as mean ±Fig. 1. mtDNA induces IL-6 and IL-8 secretion from ARPE-19 cells. (A) IL-6 and IL-8 secretion fro
1 μg/mL mtDNA. Right, quantitation by densitometry. *p b 0.05 versus control and mtDNA gr
cells 24 h after treatment with FAM-tagged mtDNA with or without transfection agent. mtDN
with 1 μg/mL mtDNA.SEM. Statistical signiﬁcance for differences between two treatment
groups was determined with Student's t-test. One-way ANOVA with
Tukey post-hoc correction was used for multiple group compari-
sons. A p-value of b0.05 was considered statistically signiﬁcant.
3. Results
3.1. mtDNA induces IL-6 and IL-8 secretion from ARPE-19
To determine the effect of mtDNA on IL-6 and IL-8 secretion from
ARPE-19 cells, a 2 kb fragment of mtDNA was ampliﬁed by PCR and
transfected into ARPE-19 cells. IL-6 and IL-8 were measured in the cul-
ture medium 48 h post-transfection by western blot. Fig. 1A shows
that mtDNA induced a 4-fold and a 2-fold increase in the secretion of
IL-6 (p b 0.001) and IL-8 (pb 0.01), respectively, compared to a transfec-
tion agent control. In contrast, neither cytokine was induced when
mtDNA was used without transfection agent. This suggests that IL-6
and IL-8 are induced by intracellular mtDNA rather than extracellular
mtDNA binding to a cell surface receptor. To conﬁrm this, labeled
mtDNA was generated by PCR using FAM-tagged primers, and ARPE-
19 cells were treated for 24 h with labeled mtDNA with or without
transfection agent. Fig. 1B shows mtDNA being present in an intracellu-
lar cytoplasmic location only when combined with a transfection agent.
This ﬁnding, in conjunction with the previous result (Fig. 1A), indicates
that only intracellular mtDNA can induce IL-6 and IL-8 secretion. To as-
sess whether the observed cytokine response was due to cell death, cell
viability was determined using an MTT assay at 48 h post-transfection
with the same mtDNA dose. mtDNA did not cause signiﬁcant cell
death compared to a transfection agent control, indicating that mtDNA
induces IL-6 and IL-8 secretion rather than merely causing cell death
and release of cytokines.m ARPE-19 as determined by western blot of culture media 48 h post-transfection with
oups; #p b 0.001 versus all other groups; §p b 0.01 versus all other groups. (B) ARPE-19
A in green, DAPI in blue. (C) ARPE-19 viability determined by MTT 48 h post-transfection
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response
To determine whether the sequence of the mtDNA fragment has any
effect on cytokine induction, four 2-kb fragments of mtDNA with differ-
ent sequences were transfected into ARPE-19 cells. They were found to
produce similar inductions of IL-6 and IL-8 (Fig. 2A), indicating that
mtDNA induces IL-6 and IL-8 in a sequence-independent fashion. Since
AMD has been associated with impaired autophagy [38] and RPE death
[39], mtDNA under such conditions may be fragmented and accumulate
in the cell in different sizes [40]. Therefore, to determine the effect of the
size ofmtDNAon IL-6 and IL-8 induction, 3mtDNA fragments of different
sizes were generated by PCR and transfected into ARPE-19 cells. The
result shows that larger mtDNA fragments induced stronger IL-6 and
IL-8 responses (Fig. 2B). Furthermore, mtDNA has been found to be
more oxidized in AMD retinas compared to age-matched controls [41].
Tomimic the in vivo situation, oxidizedmtDNAwas generated by PCR in-
corporating the modiﬁed nucleotide 8-oxoguanine and transfected into
ARPE-19 cells. This resulted in a stronger IL-6 and IL-8 secretion
compared to non-oxidized mtDNA (Fig. 2C). Finally, the time course
and dose response were evaluated, and both IL-6 and IL-8 were found
to be induced in a time and dose-dependent fashion (Fig. 2D and E).Fig. 2.Oxidized and largermtDNA fragments induce a stronger cytokine response. (A) IL-6 and IL-8 s
of different sequences but similar sizes (schematic). Right, quantitation by densitometry. (B) I
fragments of different sizes (schematic). Right, quantitation by densitometry. *p b 0.05 versu
with 1 μg/mL of mtDNA or oxidized mtDNA. Right, quantitation by densitometry. *p b 0.01 ve
mtDNA dose on IL-6 and IL-8 secretion at 48 h.3.3. mtDNA induces IL-6 and IL-8 secretion through STING
STING, an endoplasmic reticulum transmembrane protein, has been
shown to be important in the immune response to foreign DNA in the
context of infection, and self DNA in the context of autoimmunity [42].
Our experiments show that it is expressed in ARPE-19 cells and even
more so in primary human RPE cells (Fig. 3A), and this expression can
be successfully knocked down in ARPE-19 cells with siRNA speciﬁc to
STING (Fig. 3B). To explore whether STING is involved in mtDNA-
induced IL-6 and IL-8 secretion, mtDNA was transfected into ARPE-19
cells in which STING had been knocked down with siRNA. The result
shows that STING knockdown partially abrogated mtDNA-induced IL-
6 (Fig. 3C) and IL-8 (Fig. 3E) secretion, indicating that STING mediate
the induction of IL-6 and IL-8 secretion by mtDNA.
3.4. mtDNA induces IL-6 and IL-8 secretion via NF-κB
Because the NF-κB pathway has been recently shown to be activated
by STING [43,44], we sought to determinewhether it is also activated by
mtDNA. The levels of NF-κB subunit p65weremeasured by ELISA in nu-
clear isolates of ARPE-19 cells 24 h post-transfection with mtDNA.
Fig. 4B shows that mtDNA induces p65 nuclear translocation 1.4-foldecretion fromARPE-19 cells 48 h post-transfectionwith 1 μg/mL of 2-kbmtDNA fragments
L-6 and IL-8 secretion from ARPE-19 cells 48 h post-transfection with 1 μg/mL of mtDNA
s all other groups. (C) IL-6 and IL-8 secretion from ARPE-19 cells 48 h post-transfection
rsus control. (D) Time course of IL-6 and IL-8 induction by μg/mL of mtDNA. (E) Effect of
Fig. 3.mtDNA induces IL-6 and IL-8 secretion through STING. (A) STING immunoblotting of untreated ARPE-19 and primary human RPE lysates alongside a THP-1 lysate (positive control for
STING). 40 μg of total protein loaded per lane. Prominent band seen at STING's predicted molecular weight (≈40 kDa). (B) ARPE-19 cells were treated for a total of 96 h with 20 nM of
either STING siRNA or control siRNA and lysates immunoblotted with STING monoclonal antibody. Right, quantitation by densitometry. *p b 0.001 versus control siRNA. (C&D) Along
with mtDNA transfection, ARPE-19 cells were pre and co-treated with STING or control siRNA, and culture media were collected at 48 h and subjected to western blot for IL-6 (C) and
ELISA for IL-8 (D), as western blot did not provide sufﬁcient resolution to study differences in IL-8 levels. *p b 0.05; §p b 0.01 versus all other groups.
2901B. Dib et al. / Biochimica et Biophysica Acta 1853 (2015) 2897–2906(p b 0.01).mtDNA also induces the expression of A20 (Fig. 4C), amarker
of NF-κB activation. These results together indicate that mtDNA
activates the NF-κB pathway. To test whether NF-κB mediates the IL-6
and IL-8 induction by mtDNA, ARPE-19 cells were brieﬂy pre-
incubated with different concentrations of an NF-κB inhibitor (Bay 11-
7082) beforemtDNA transfection. This led to a dose-dependent abroga-
tion of mtDNA-induced IL-6 and IL-8 secretion (Fig. 4D), indicating that
the NF-κB pathway is involved in mediating IL-6 and IL-8 induction by
mtDNA.3.5. mtDNA primes the NLRP3 inﬂammasome through STING and NF-κB
Since the NLRP3 inﬂammasome is primed by NF-κB [34,45,46], we
hypothesized that mtDNA could also prime the NLRP3 inﬂammasome.
To test this hypothesis, the levels of the pro-forms of IL-1β, IL-18, and
caspase-1 in ARPE-19 cells transfected with mtDNA were analyzed by
western blot. The result shows that mtDNA upregulates pro-IL-1β 2.4-
fold (p b 0.05) and pro-caspase-1 1.4-fold (p b 0.05) compared to con-
trol (Fig. 5A), indicating that mtDNA primes the NLRP3 inﬂammasome.
In contrast, mtDNA did not change the level of pro-IL-18 (Fig. 5A). To
test whether the pro-IL-1β induction is mediated by STING and NF-κB,
the same inhibition strategy used previously was followed. The result
shows that mtDNA induces pro-IL-1β via STING, as evidenced by abro-
gation of the inductionwith STING knockdown (Fig. 5B). Also, NF-κB in-
hibition dose-dependently abrogated the induction (Fig. 5C), indicating
that mtDNA induces pro-IL-1β through the NF-κB pathway. Togetherthese ﬁndings indicate that mtDNA primes the NLRP3 inﬂammasome
through a STING/NF-κB pathway.3.6. mtDNA and the NLRP3 inﬂammasome in the RPE
To determine whether mtDNA also activates NLRP3, we performed
ELISA for mature IL-1β and IL-18 on the culture medium of ARPE-19
48 h post-transfection with mtDNA. Fig. 6A shows that, in ARPE-19
cells, mtDNA induces secretion of IL-1β 5.9-fold compared to control
(p b 0.01, n = 4), but not IL-18. Although these ELISA assays are de-
signed to detect the mature forms of IL-1β and IL-18, the pro forms of
these cytokines do cross-react if present in high quantities. For this rea-
son, western blotting was performed yet repeatedly failed to detect any
mature form in either cell lysates or culture media. This is not due to
technical difﬁculties on our part since we could detect the mature
form of IL-1β in THP-1 cells after mtDNA transfection Fig. 6B,C. The
major caspase involved in thematuration of IL-1β is caspase 1. Its activ-
ity was assessed in ARPE-19 cells 24 h after mtDNA transfection using
FAM-YVAD-FMK probe, a ﬂuorochrome-labeled inhibitor of caspase
(FLICA) that ﬂuoresces when bound to active caspase-1. Imaging
showed that cells transfected with mtDNA had increased FAM-YVAD-
FMK signal (Fig. 6D), suggesting potential activation of caspase-1 by
mtDNA in ARPE-19 cells.
It should be noted however that concerns about the speciﬁcity of the
latter probe have been raised [82]. In fact, only a minor fraction of FLICA
signal could be attributed to its interactionwith the respective caspases.
Fig. 4.mtDNA induces IL-6 and IL-8 secretion via NF-κB. (A) Nuclear fractionation efﬁciency veriﬁed with TATA-binding protein (TBP) and β-tubulin. (B) p65 NF-κB ELISA performed on
nuclear isolates of ARPE-19 cells 24 h post-transfection with mtDNA. *p b 0.01 versus control. (C) A20 expression level 48 h post-transfection of mtDNA. Right, quantitation by densitom-
etry. *p b 0.05 versus control. (D) ARPE-19 cells were pre-incubated for 30 min with an irreversible NF-κB inhibitor (Bay 11-7082) before mtDNA transfection. After 48 h, culture media
were collected and immunoblotted for IL-6 and IL-8. Right, quantitation by densitometry. *p b 0.05 versus control and [mtDNA + Bay μM] groups.
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unproven.
4. Discussion
AMD is associated with a number of risk factors, including age,
smoking, obesity and cardiovascular disease. Despite the uncertainty
surrounding the pathophysiology of this disease, the last decade has
seen increasing evidence to support a role for mitochondrial dysfunc-
tion in its development [4–7]. Compared to age-matched controls, RPE
cells of AMD patients have been reported to have a decline in the num-
ber and structural integrity of mitochondria [8] as well as a decreased
content of electron transport chain proteins [47], indicating impaired
mitochondrial biogenesis even at early stages of AMD. Furthermore,
damage to mtDNA has been documented in the RPE of AMD patients
even before vision loss occurs [5–7], suggesting the potential beneﬁt
of early interventions to rescue mitochondrial function in slowing
down disease progression. Recent work has also identiﬁed a role not
only for damaged mtDNA but also for inherited mitochondrial DNA
variants [48]. In that study Kenney et al. found that J and H cytoplasmic
hybrids have signiﬁcantly altered expression of several nuclear
genes involving alternative complement, inﬂammation and apoptosis
pathways. The same group in a separate study [49] has also found
that mtDNA variants mediate energy production and expression
levels for CFH, C3 and EFEMP1, genes known to be involved in AMD
[50–57]. Since altered mitochondrial function is not only present but
also likely contributory to AMD progression, we postulated release of
inﬂammatogenic mtDNA as a potential mechanism for disease
perpetration.
In fact, a wealth of evidence supports a role for inﬂammation in the
development and progression of AMD [35,58]. Speciﬁcally, clinical and
genetic studies have revealed the importance of IL-6 and IL-8 in the
pathogenesis of AMD. IL-6 is a pleiotropic inﬂammatory cytokine thatcan exaggerate immune and inﬂammatory responses, and its level has
been associated with AMD onset [24] and progression [22]. IL-8 is a
member of the CXC chemokine family and a potent chemoattractant
for neutrophils and monocytes, and IL-8 haplotypes have been found
to confer an increased risk of AMD [21,23,25]. In our study, intracellular
mtDNA induced IL-6 and IL-8 secretion from ARPE-19 cells, suggesting
that mtDNA can potentially contribute to the inﬂammatory component
of AMD. Both interleukins studied have also been associated with
neovascular (wet) AMD, as they have been correlated with CNV and
macular thickness in exudative AMD [27,28]. Furthermore, both cyto-
kines are pro-angiogenic and induce VEGF [59–62], a crucial factor in
CNV development. In aged RPE cells with compromised mitochondrial
integrity, mtDNAmolecules that leak into the cytosol may therefore po-
tentiate a local inﬂammatory microenvironment that furthers progres-
sion of AMD and CNV. This phenomenon may be even more
prominent in situations where mtDNA degradation is impeded, such
as impaired autophagy in the RPE. The latter phenomenon has been as-
sociated with AMD [38], and it could cause accumulation of damaged
organelles and molecules in the RPE, including mtDNA. Our experi-
ments show that larger mtDNA fragments and higher mtDNA doses
cause more IL-6 and IL-8 secretion. These ﬁndings suggest that RPE
cells in AMDmay be evenmore susceptible to mtDNA-induced damage
due to their declining autophagic function and an inability to break
down mtDNA into its basic nucleotide constituents.
Oxidative stress has also been implicated in aging and AMD [63],
and part of the evidence comes from genetic studies that showed an as-
sociation between antioxidant enzyme gene polymorphisms and AMD
[64,65]. Furthermore, mitochondria are the main cellular source of oxi-
dative stress [66], and mtDNA has been found to be oxidized in AMD
retinas [41]. In our study, oxidized mtDNA induced a stronger IL-6 and
IL-8 response compared to non-oxidized mtDNA. This suggests that
mtDNAmay be evenmore pro-inﬂammatory in AMD patients by virtue
of its oxidized status, worsening a vicious cycle of inﬂammation and
Fig. 5.mtDNA primes the NLRP3 inﬂammasome through STING and NF-κB. (A) Immunoblots of ARPE-19 lysates 48 h after mtDNA transfection. Right, quantitation by densitometry. *p b 0.05
versus control. (B) AlongwithmtDNA transfection, ARPE-19 cells were pre and co-treatedwith STING or control siRNA, and lysates were collected at 48 h and immunoblotted for
pro-IL-1β. Right, quantitation by densitometry. *p b 0.05 versus all other groups. (C) ARPE-19 cells were pre-incubated for 30 min with an irreversible NF-κB inhibitor (BAY 11-7082)
before mtDNA transfection. After 48 h, lysates were collected and immunoblotted for pro-IL-1β. Right, quantitation by densitometry. *p b 0.05 versus all other groups.
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the RPE. This phenomenonmay be particularly pronounced in AMDvar-
iants with compromised anti-oxidative defense mechanisms [64,65].
Although our ﬁndings indicate that induction of IL-6 and IL-8 was
independent of mtDNA sequence, we cannot exclude the importance
of nucleotide composition, especially in oxidative situations where dif-
ferential nucleotide susceptibility to oxidation will translate into differ-
ent overall oxidative charges across fragments with different nucleotide
constitutions. Studying this phenomenon would also require the use ofsmaller mtDNA fragments where dissimilar nucleotide compositions
are more likely to be found.
Extracellular mtDNA had no detectable effects on either IL-6 or IL-8
secretion, at least within the resolving capacity of western blot. This
could be explained by a lack of surface receptors for mtDNA on ARPE-
19 cells. Practically all the DNA sensors described to date are intracellu-
lar [36], including Toll-like receptor 9 (TLR9), a transmembrane recep-
tor of unmethylated CpG motifs that has been conﬁrmed to be
predominantly intracellular rather than on the cell membrane [67,68],
Fig. 6.mtDNA and the NLRP3 inﬂammasome in the RPE. (A) IL-1β and IL-18 ELISA on culture media of ARPE-19 cells 48 h post-transfection with mtDNA. Results are mean ± SEM, n = 4.
Please note that levels of IL1β are orders of magnitude below levels seen frommacrophages. *p b 0.01 versus control. (B) IL-1β and IL-18 ELISA on culture media of THP-1 cells 24 h after
transfectionwithmtDNA. *p b 0.001 versus control. (C) IL-1β immunoblotting on culturemedia of THP-1 cells 24 h after transfectionwithmtDNA. (D) ARPE-19 caspase-1 activity assessed
24 h after mtDNA transfection using ﬂuorescent FLICA probe FAM-YVAD-FMK.
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vious evidence that extracellular mtDNA has no immunostimulatory
effect unless used with a molecule that aids its uptake into the cell [20,
70]. In other studies, extracellularmtDNAwasmildly immunostimulatory
in certain cell types, but only at very high concentrations (N10 μg/mL) [13,
20]. In ARPE-19 cells, extracellular CpGDNAhas been shown to induce IL-
8 secretion only at the dose of 84 μg/mL, almost 2 orders of magni-
tude higher than the concentration we used, and this effect was
attributed to CpG DNA that had been internalized by phagocytosis
[69].
Although it remains unclear which DNA sensors are involved in
sensing intracellular mtDNA, we have identiﬁed STING as an important
downstream mediator of the inﬂammatory pathways triggered by
mtDNA in ARPE-19 cells as evidenced by STING knockdown experi-
ments. This transmembrane endoplasmic reticulum protein has been
clearly demonstrated to take center stage in the response to intracellu-
lar foreign and self-DNA [36,42]. Unlike DNA sensors, which exhibit
overlapping and redundant functions, STING seems to constitute a com-
mon downstreamnode tomost DNA-sensing pathways, a property that
might be advantageous in therapeutic efforts to modulate the innate
immune defenses of the cell. Our study extends the importance of
STING to RPE cells in their inﬂammatory response to mtDNA. To our
knowledge, this is the ﬁrst report of STING or any DNA sensing function
in RPE cells. Such knowledge may prove valuable in understanding the
consequences of insufﬁcient autophagy in the face of the highmetabolic
demands that constantly weigh on the aging RPE. Once activated, STING
can in turn stimulate NF-κB [43,44]. Our ﬁndings indicate that mtDNA
can indeed activate this latter pathway. NF-κB blockade has been
shown to inhibit choroidal neovascularization [71,72], highlighting the
importance of NF-κB in the progression of AMD. NF-κB also regulates
the expression of many genes in RPE cells, including IL-6 and IL-8 [73,
74], and this is corroborated by our experiments of NF-κB inhibition
abrogating the induction of cytokines.Recent studies have shown NF-κB to be critical for priming of the
NLRP3 inﬂammasome in RPE cells [75]. The NLRP3 inﬂammasome has
recently received widespread attention for its possible association
with both atrophic (dry) and neovascular (wet) AMD [31–33], and sev-
eral stimuli have been shown to trigger its activation in ARPE-19 cells
[76–80]. We found that mtDNA primes but does not conclusively acti-
vate the NLRP3 inﬂammasome through a STING/NF-κB pathway as evi-
denced by upregulation of the pro-forms of IL-1β and caspase-1 but
minimal upregualtion of themature form. Pro-IL-18 appeared to be con-
stitutively expressed in our cells, which is in accordance with previous
ﬁndings in ARPE-19 [76,81] and other cell types [34]. Our data suggests
a potential low-level activation of the NLRP3 inﬂammasome by mtDNA
in ARPE-19 cells as evidenced by secretion of low levels of mature IL-1β
to the culture medium and increased FAM-YVAD-FMK signal. It should
be noted however that concerns about the speciﬁcity of FLICA probe
have been raised [82]. In fact, only a minor fraction of FLICA signal
could be attributed to its interaction with the respective caspases [82].
Thus conclusive activation of inﬂammasome in RPE cells remains un-
proven. More importantly, because of differences and serious deﬁcien-
cies in AMD experimental models, there is still no consensus as to
whether NLRP3 activity is detrimental or protective in the ﬁrst place.
One study suggested a protective effect on CNV through the anti-
angiogenic effect of IL-18 using an acute laser-injury CNV model [33],
whereas another study suggested a detrimental effect through IL-1β
using a VEGF-A-overexpressing mouse [31]. The role of these cytokines
in the pathogenesis of AMD remains unclear. Our data unfortunately
cannot argue one way or another. The low-level inﬂammasome activa-
tion that we observed could be compensatory and protective, or detri-
mental, or even just a “spillover” of overall inﬂammation. In addition,
NLRP3 activation in RPE cells is orders of magnitude less than that of in-
ﬂammatory cells, and it still remains to be answered if a chronic low-
level activation of the inﬂammasome in RPE cells could play a role in
the evolution of AMD. One can argue that in contrast to acute
2905B. Dib et al. / Biochimica et Biophysica Acta 1853 (2015) 2897–2906inﬂammatory processeswhere highly potent inﬂammatory cellsmay be
needed, AMD and other chronic diseases such as atherosclerosis are
characterized by a state of para-inﬂammation [83,84], a termused to de-
scribe a response to stress that is intermediate between the basal state
and inﬂammation. In our study, we found that mtDNA could induce se-
cretion of the mature form of IL-1β in THP-1 cells Fig 6 B,C, a macro-
phage cell line, indicating that mtDNA can activate NLRP3 in
macrophages, consistent with previous reports in bone-marrow-
derivedmacrophages [29,30]. This suggests a role for agedmacrophages
in licensing NLRP3 activation within the retinal microenvironment
when exposed to their own accumulated mtDNA or mtDNA that has
been phagocytized from dying retinal cells such as the RPE. Moreover,
previous evidence of a direct physical interaction between mtDNA and
NLRP3 [30] makes the applicability of NLRP3 activation by mtDNA in
other cell types more plausible, at least conceptually.
In summary, this study elucidates the pro-inﬂammatory properties
of mtDNA in ARPE-19 cells and suggests inﬂammation as a plausible
mechanistic link between mitochondrial damage and AMD, one in
which accumulatingmtDNA in aged RPE cells can create an inﬂammato-
ry microenvironment that aids in the development and progression of
AMD. Our ﬁndings also suggest STING and NF-κB as interesting thera-
peutic targets to explore in the future for the purpose of modulating in-
nate immune defenses in the aging RPE.
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